jRCT2031210266已完成不适用
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study of SR-0379 in Participants with Skin Ulcer
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 120
- 主要终点
- -
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized Controlled Trial
- 干预模型
- Parallel Assignment
- 主要目的
- Treatment Purpose
- 盲法
- Double Blind
入排标准
- 年龄范围
- 18age old over 至 85age old not（—）
- 性别
- All
入选标准
- •Patients must have a wound requiring wound bed preparation in advance of planned surgical closure (including suturing, grafts or flaps)
排除标准
- •Presence of untreated ulcer infection (redness, swelling, pus, foul odor, fever)
结局指标
主要结局
-
The days to simple surgical intervention (ncluding suturing, grafts or flaps)
次要结局
未报告次要终点
研究者
相似试验
进行中（未招募）
1 期
Efficacy and Safety of Certolizumab Pegol in Subjects with Moderate to Severe Chronic Plaque PsoriasisMedDRA version: 20.0Level: LLTClassification code 10071117Term: Plaque psoriasisSystem Organ Class: 100000004858Plaque PsoriasisEUCTR2014-003513-28-CZCB Biopharma, SPR225
进行中（未招募）
1 期
Study to Evaluate how effective and safe the investigationall product, Mitapivat, is when administred to Pediatric Subjects With Pyruvate Kinase Deficiency, who are not receiving regular blood transfusions, followed by a 5-Year Open-label Extension Period, where subjects will be given the option to receive mitapivat for an additional 5 years.Pyruvate Kinase DeficiencyMedDRA version: 21.1Level: PTClassification code: 10037682Term: Pyruvate kinase deficiency anaemia Class: 100000004850CTIS2024-515025-28-00Agios Pharmaceuticals Inc.29
进行中（未招募）
1 期
A Phase 3 Study of Guselkumab in Subjects with Active Psoriatic ArthritisActive Psoriatic ArthritisMedDRA version: 21.0Level: LLTClassification code 10037160Term: Psoriatic arthritisSystem Organ Class: 100000004859EUCTR2016-001224-63-LTJanssen-Cilag International N.V.684
进行中（未招募）
不适用
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial Comparing the Efficacy and Safety of Tafasitamab Plus Lenalidomide in Addition to R-CHOP Versus R-CHOP in Previously Untreated, High-intermediate and High-risk Patients With Newly-diagnosed Diffuse Large B-cell Lymphoma (DLBCL) (frontMIND)jRCT2071220021Incyte Biosciences Japan G.K.880
进行中（未招募）
1 期
Study to Evaluate how effective and safe the investigationall product, Mitapivat, is when administred to Pediatric Subjects With Pyruvate Kinase Deficiency, who are receiving regular blood transfusions, followed by a 5-Year Open-label Extension Period, where subjects will be given the option to receive mitapivat for an additional 5 years.Pyruvate Kinase DeficiencyMedDRA version: 21.1Level: PTClassification code 10037682Term: Pyruvate kinase deficiency anaemiaSystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2021-003265-36-ESAgios Pharmaceuticals, Inc.45